Pharmaceutical Companies Partner With Bioinformatics Institutes to Reduce Drug Development Failures

Drug development is a risky business, with an estimated 90 percent of compounds that enter clinical trials ultimately failing to reach the market.
Published Online: March 28, 2014

Governments, academic groups and drugmakers have been seeking to improve those odds through partnerships that bring together the expertise of scientists in a broad array of fields, from biology to genomics. The goal is to identify biological targets for drugs and weed out failures before they reach human testing.

The latest such initiative comes from GlaxoSmithKline Plc, the European Bioinformatics Institute and the Wellcome Trust Sanger Institute, all based in the U.K. The partners will establish the new Centre for Therapeutic Target Validation, to be located near Cambridge, England. By harnessing the latest advances in genomics and the growing ability to gather and analyze large sums of biological data, they seek to eliminate development of drugs that target the wrong biological pathways, pre-empting billions of dollars of wasted research spending.

Read the story here: 
http://bloom.bg/1fosDMq

S
ource: Bloomberg News



Feature
Recommended Articles
A study published in JAMA Oncology presents a new tool that can predict disease recurrence in oropharyngeal cancer patients.
Healthcare spending growth between 2014 and 2024 is projected to be substantially lower than the 3 decades prior to 2008, according to a new report from CMS. In addition, the average premium for a basic Medicare Part D prescription plan will remain stable in 2016.
Urologists at Cancer Research UK have identified 5 distinct genomic signatures in prostate cancer that can have important implications on treatment decisions.
New research studies show that anti-inflammatory agents can improve survival as well as quality of life in cancer patients.
America currently has a heroin problem. Can private sector innovations help?